MFS Capital Partners Limited (JMSE:MFS)
Jamaica · Delayed Price · Currency is JMD 0.3700
0.00 (0.00%)
At close: Aug 4, 2025
CTI BioPharma Income Statement
Financials in millions JMD. Fiscal year is July - June.
Millions JMD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2016 - 2020 |
Operating Revenue | 209.71 | 28.54 | - | - | 19.7 | 116.76 | Upgrade |
| 209.71 | 28.54 | - | - | 19.7 | 116.76 | Upgrade | |
Revenue Growth (YoY) | - | - | - | - | -83.13% | -64.86% | Upgrade |
Cost of Revenue | 86.17 | - | 0.03 | 0.12 | 20.28 | 107.02 | Upgrade |
Gross Profit | 123.54 | 28.54 | -0.03 | -0.12 | -0.58 | 9.74 | Upgrade |
Selling, General & Admin | 85.9 | 69.17 | 16.1 | 36.75 | 46.49 | 108.02 | Upgrade |
Other Operating Expenses | -61.18 | -1.63 | -29.23 | -66.03 | -322.65 | -42.82 | Upgrade |
Operating Expenses | 25.64 | 68.19 | -12.38 | -27.42 | -272.83 | 78.25 | Upgrade |
Operating Income | 97.91 | -39.66 | 12.35 | 27.3 | 272.25 | -68.51 | Upgrade |
Interest Expense | -7.47 | -1.88 | -0.25 | -1.13 | -9.4 | -15.22 | Upgrade |
Interest & Investment Income | 6.15 | 6.12 | 0.02 | 0 | 0.04 | 0.06 | Upgrade |
Earnings From Equity Investments | 0.26 | 0.26 | - | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | 1.06 | 1.06 | -0 | - | -0.51 | -0.87 | Upgrade |
Other Non Operating Income (Expenses) | -13.62 | -11.71 | -2.2 | -5.94 | -50.26 | -17.94 | Upgrade |
EBT Excluding Unusual Items | 84.28 | -45.81 | 9.91 | 20.23 | 212.11 | -102.48 | Upgrade |
Impairment of Goodwill | - | - | - | - | - | -53.81 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | -0.34 | -2.06 | 0.18 | -13.47 | Upgrade |
Pretax Income | 84.28 | -45.81 | 9.57 | 18.17 | 212.29 | -169.76 | Upgrade |
Income Tax Expense | 24.8 | 6.28 | 0.82 | - | 47.45 | -16.93 | Upgrade |
Earnings From Continuing Operations | 59.49 | -52.08 | 8.74 | 18.17 | 164.84 | -152.83 | Upgrade |
Minority Interest in Earnings | 0.02 | 2.52 | 0.05 | -5.33 | -5.92 | 13.88 | Upgrade |
Net Income | 59.51 | -49.56 | 8.79 | 12.84 | 158.92 | -138.94 | Upgrade |
Net Income to Common | 59.51 | -49.56 | 8.79 | 12.84 | 158.92 | -138.94 | Upgrade |
Net Income Growth | - | - | -31.52% | -91.92% | - | - | Upgrade |
Shares Outstanding (Basic) | 600 | 405 | 400 | 400 | 400 | 400 | Upgrade |
Shares Outstanding (Diluted) | 600 | 405 | 400 | 400 | 400 | 400 | Upgrade |
Shares Change (YoY) | 50.07% | 1.25% | - | - | - | - | Upgrade |
EPS (Basic) | 0.10 | -0.12 | 0.02 | 0.03 | 0.40 | -0.35 | Upgrade |
EPS (Diluted) | 0.10 | -0.12 | 0.02 | 0.03 | 0.40 | -0.35 | Upgrade |
EPS Growth | - | - | -31.52% | -91.92% | - | - | Upgrade |
Free Cash Flow | -74.16 | -50.88 | -17.55 | 29.87 | 263.59 | -141.3 | Upgrade |
Free Cash Flow Per Share | -0.12 | -0.13 | -0.04 | 0.07 | 0.66 | -0.35 | Upgrade |
Gross Margin | 58.91% | 100.00% | - | - | -2.96% | 8.34% | Upgrade |
Operating Margin | 46.69% | -138.97% | - | - | 1382.15% | -58.68% | Upgrade |
Profit Margin | 28.38% | -173.67% | - | - | 806.80% | -119.00% | Upgrade |
Free Cash Flow Margin | -35.36% | -178.28% | - | - | 1338.20% | -121.02% | Upgrade |
EBITDA | 98.56 | -39.01 | 13.1 | 29.12 | 274.34 | -64.07 | Upgrade |
EBITDA Margin | 47.00% | -136.69% | - | - | 1392.74% | -54.87% | Upgrade |
D&A For EBITDA | 0.65 | 0.65 | 0.75 | 1.82 | 2.09 | 4.44 | Upgrade |
EBIT | 97.91 | -39.66 | 12.35 | 27.3 | 272.25 | -68.51 | Upgrade |
EBIT Margin | 46.69% | -138.97% | - | - | 1382.15% | -58.68% | Upgrade |
Effective Tax Rate | 29.42% | - | 8.61% | - | 22.35% | - | Upgrade |
Advertising Expenses | - | 1.06 | 0.43 | - | 0.01 | 0.65 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.